Because the therapeutic applications of stem cell exosomes are expanding, innovation within the market is also accelerating. New trends have emerged, including the use of stem cell exosomes as diagnostic tools and cell-free therapeutics. Additionally, numerous life science companies are offering tools and reagents to support exosome research.
Similarly, techniques for large-scale clinical-grade manufacture of stem cell exosomes is becoming a focal point within the industry, as highlighted by a recent partnership between RoosterBio and Exopharm, as well as Lonza’s intentions to enter the market through it recent acquisitions of HansaBioMed Life Sciences and investment into Exosomics made in May 2017. [Read more…]